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Abstract
The purpose of family psychoeducation is to increase patients’ and their 
families’ knowledge and understanding of their illness and treatment. Improved 
knowledge of schizophrenia is expected to enable people to cope better with 
their illness. The aim of this review is to summarize and appraise evidence from 
published systematic and meta-analytic reviews on family psychoeducation in 
schizophrenia. Thorough search and analysis of reviews on efficacy of family 
psychoeducation in schizophrenia were carried out in PubMed/Medline (1987-
2015), Ovid/Psych Info (1987-2015), and the Cochrane Database of Systematic 
Reviews. We included only reviews reporting quantitative summary statistics on 
studies carried out in patients with schizophrenia and written in English. Review 
methodology was assessed using the Assessment of Multiple Systematic 
Reviews (AMSTAR) checklist. Double check by two independent assessors 
was applied. Nine reviews meeting inclusion/exclusion criteria were included in 
the meta-review. Risk of relapse was reduced in protocols that included family 
members, whether conducted in single family or in multifamily group sessions. 
However, effectiveness seems not to be maintained at follow-up. Hospital 
admission/re-hospitalization was less influenced by family psychoeducation, 
and no reproducible effect on compliance/medication adherence was found. 
Overall, quality of evidence on the effectiveness of family psychoeducation in 
schizophrenia is poor.
Keywords: Schizophrenia; Psychoeducation; Family; Interventions; Meta-
analysis; Meta-review
Introduction
Schizophrenia and related psychoses are severe mental disorders 
with a high impact in terms of disability and poor quality of life. The 
clinical course of schizophrenia is typically one of highly recurrent 
acute episodes with chronic impairment of social, vocational and 
personal wellbeing [1-3]. The costs for patients, their families and 
society are huge, and largely generated by the direct cost of care, 
especially hospitalization [4-6].
Currently, pharmacotherapy is the most important therapeutic 
intervention in the treatment of schizophrenia-spectrum psychoses. 
However, response rate is limited to 60% of treated patients, and 
about 1 in 3 people have an illness with a “treatment resistant” course 
[7,8].
Many educational programs have been aimed at improving 
knowledge of the disorder, its symptoms, course and outcome, and 
the availability of treatment, and have focused specifically on the 
patients and their families [9-14].
The purpose of family psychoeducation is to increase patients’ 
and their families’ knowledge and understanding of their illness 
and treatment. Improved knowledge of schizophrenia is expected 
to enable people to cope better with their illness [9,15,16]. Studies 
on the effectiveness of these programs have found medium-
sizedprotective effects against the risk of relapse and the probability 
of readmission [12,14]. Overall, evidence on the effectiveness of 
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family psychoeducationin schizophrenia is sparse, and it is unclear 
what specific outcomes are affected and how. The aim of this review is 
to summarize and appraise evidence from published systematic and 
meta-analytic reviews on family psychoeducation in schizophrenia.
Methods
Search was based on the following electronic databases: PubMed/
Medline (1987-2015), Ovid/Psych INFO (1987-2015), and Cochrane 
Database of Systematic Reviews (Issue 2 of 12, February 2016). A 
combination of the following keywords was used: (1) type of paper: 
systematic review or meta-analysis; (2) population: psychosis or 
schizophrenia; (3) intervention: family psychoeducation. Only 
published studies in English were included: there is evidence that 
“systematic reviews that are based on a search of English language 
literature that is accessible in the major bibliographic databases will 
often produce results that are close to those obtained from reviews 
based on more comprehensive searches that are free of language 
restrictions” [17]. The so-called “gray” literature was excluded, since 
selection bias in unpublished literature searches was found to be 
higher than in published literature [17,18].
Retrieved abstracts were scanned for relevance, and the full paper 
was retrieved only for the studies matching the inclusion criteria. The 
reference list of the retrieved reviews was examined, too, to identify 
potential additional studies. We included only reviews reporting 
summary statistics on family psychoeducation from studies carried 
out in patients with schizophrenia.
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Two authors assessed all the retrieved articles for inclusion, on 
the basis of their titles and abstracts. Two more authors (DRP and 
CL) independently assessed the selected records again and inspected 
the full article for inclusion criteria. Two authors extracted the 
data, and disagreements were solved by discussion. Two authors, 
other than those who extracted the data, assessed the quality of the 
reviews independently using the Assessment of Multiple Systematic 
Reviews (AMSTAR) checklist [19]. The tool consists of 11 items and 
was proved to possess good face, reliability and content validity for 
measuring the methodological quality of systematic reviews [20]. 
Disagreements were solved by discussion.
Grading of evidence was estimated according to the 
recommendations of the Grading of Recommendations Assessment, 
Development and Evaluation (GRADE) system, which takes into 
account how the evidence was achieved (RCTs versus observational 
trials or case reports), inconsistency of results (which is inferred 
by significant heterogeneity of the study results), indirectness of 
evidence (which is inferred by the use of approximate population level 
measures), imprecision (which pertains to wide confidence intervals 
[CI], continuous data with CI>0.5, and binary and correlation data 
with CI>0.25 in either direction), and the risk of bias in the trials 
[21,22]. Three additional factors (large magnitude of effect, dose-
response, and confounders) may lead to rating up the quality of 
evidence.
Results
The search strategy identified 9systematic or meta-analytic 
reviews (see Flowchart Diagram).
Excluded reviews (n=24) did not report quantitative summary 
statistics on the reviewed studies, or were on samples other than 
patients diagnosed with schizophrenia, or were not focused on the 
topic of interest.
The main characteristics of the included reviews are summarized 
in Table 1.
There was a wide variability in the year range of the studies 
considered in the reviews, and this corresponded to a wide variability 
in the number of included studies. Eight out of nine reviews 
incorporated a meta-analysis of the findings, which is summarized 
in Table 2.
Target outcomes in the reviews
The main outcomes considered in the reviews were frequency of 
relapse, number of re-hospitalizations, and medication adherence/
compliance. Only two reviews considered suicide or total mortality, 
and just one review summarized data on clinical global response and 
on service utilization. In the subsequent analyses we focused on hard 
indicators of effectiveness: relapse, re-hospitalization and medication 
adherence/compliance.
Sample characteristics
Most reviews focused on patients diagnosed with schizophrenia, 
but some of the included reviews also included heterogeneous 
samples of patients with serious mental illness or psychoses related 
to schizophrenia. In general, no detail was offered on how the 
diagnosis of schizophrenia was done, and information on gender and 
age composition of the samples was rarely provided. Overall sample 
size of the meta-analyses was always above 1000 participants, but the 
single studies had a sample size below 100 participants on average.
Study overlap
To have a grasp of the extent of overlap of primary studies 
among the reviews, we compared the samples of the oldest and of 
the most recent reviews, and calculated the rate of reviewed articles’ 
overlap between the two reviews; we applied the same calculation to 
quantifythe degree of overlap between the oldest and the most recent 
reviews among those that we judged to have the best quality [12,23].
There was no overlap between the oldest review [13] and the most 
Author(s) 
(Year) 
Professional 
field of the 
reviewers
Type of review Topic of review No. of reviewed studies
Year range of 
the studies
Total no. of 
subjects
Outcome 
variables
1 [24] Psychiatry Systematic review Psychoeducation in schizophrenia k=15 1966-1993 1341 - relapse
2 [39] Psychiatry Systematic review Psychosocial treatment in schizophrenia k= 16 1978-1995 4099 - relapse
3 [40] Psychiatry Meta-analysis Family Interventions in Schizophrenia k=25 1977-1997 2.692 - relapse
4 [23] Psychiatry
Systematic review 
& meta-analysis Schizophrenia or relatedserious mental illness k=10 1966-1999 1125
- relapse
- rehospitalisation
5 [27] Psychiatry Systematic review & meta analysis
Family intervention and cognitive 
behaviour therapy in schizophrenia or 
related disorder  
k=18 1980-1999 1467 - relapse- readmission
6 [41] Psychiatry Systematic review Psychosocial interventions for improving medication adherence in schizophrenia
Psychoeducation
k=12 1980-2000
1409 (cal-
culated)
- medication 
adherence
7 [28] Psychiatry
Systematic review 
& meta analysis
Family psychosocial interventions in 
schizophrenia or schizophrenia-like 
conditions
k=53 1978-2008 4444 - relapse
8 [12] Psychology Meta-analysis Psychoeducation in psychotic disorders (schizophrenia) k=18 1982-2005 1534
- relapse
- rehospitalization
- medication 
adherence
9 [14] Psychiatry
Systematic review 
& meta analysis Family psychoeducation (FPE) k= 44 1988 - 2009 5142
- relapse
- readmission
- compliance
Table 1: Characteristics of reviews which met the inclusion criteria.
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Study Outcome k n patients Effect Size
 [24] Relapse 11 693
1. Six crisis-oriented, brief weekly sessions vs. Medium- and low-dose medication: 
Significantly lower relapses in family crisis intervention
2. Behavioral family therapy vs. Supportive individual psychotherapy with brief family counselling:
Significantly fewer relapses in family treatment group
3. Education of relatives vs. Regular hospital follow-up, little family contact: 
Significantly reduced relapses for family treatment group
4. Education and discussion in patient-only and relative-only groups vs. Standard aftercare: 
No differences in relapse
5. Education, discussion, communication, and problem-solving training vs. Day hospital alone, 
social skills training: 
Family treatment significantly reduced relapse
6.Behavioral program vs. Education only: 
Family treatment significantly reduced relapse
7. Education, discussion, family therapy in the
home vs. Education plus relatives' support group:
No significant differences between the groups in relapse
8. 10-week program for relative oriented to building alliance and problem solving vs. Standard 
outpatient care: 
No difference in relapse
9. Clinic-based behavioral family management
developed by Falloon vs. Standard services: 
Treatment group had significantly fewer relapses
10. Psychoeducational multifamily group vs.  psychoeducational single-family therapy, dynamic 
multifamily therapy:
Psychoeducational multifamily group had significantly less relapses
11. Psychoeducational multifamily group vs. Psychoeducational single-family group: 
Significantly fewer relapses in multifamily group
[42] Relapse 12 3732
Family intervention equal to standard care: k = 2
Family intervention better than standard care: k =7
Cannot answer: k = 3 
[41]
Relapse
12 874 Comparison I: family intervention vs. usual careeffect size*: r= 0.20 [0.14-0.27]
Relapse 5 523 Comparison II: family intervention + patient intervention vs. usual careeffect size*: r= 0.18 [0.09-0.26]
[23]
Relapse 6 720
Any form of psychoeducation vs. standard care
With or without readmission – over 9-18 months
RR= 0.80 [0.70, 0.92]
Relapse 3 385
Any form of psychoeducation vs. standard care -
Without readmission
RR=1.05 [0.84, 1.31]
Relapse 2 303
Any form of psychoeducation vs. standard care -
By 1 year
1.16 [0.92, 1.46]
Relapse 1 82
Any form of psychoeducation vs. standard care -
By 18 months
RR= 0.5 [0.23, 1.11]
Re-hospitalisation 1 82
Any form of psychoeducation vs. standard care -
By 18 months
RR=0.56 [0.28, 1.12]
Relapse 2 114 Standard length group psychoeducation vs. standard care - Without readmissionRR=0.58 [0.34, 0.99]
Relapse 1 32 Standard length group psychoeducation vs. standard care- By 9 monthsRR= 0.7 [0.36, 1.37]
Relapse 1 82 Standard length group psychoeducation vs. standard care -By 18 months:RR=0.5 [0.23, 1.11]
Re-hospitalisation 1 82 Standard length group psychoeducation vs. standard care -By 18 months: RR=0.56 [0.28, 1.12]
[27]
Relapse 11 729
1st 12 months v. all other treatments
Fixed effects odds ratio/ effect size= 0.63 [0.46 – 0.86]
Random effects odds ratio/ effect size= 0.52 [0.31 – 0.89]
Relapse 6 355
1st 12 months v. standard care
Fixed effects odds ratio/ effect size= 0.37 [0.23 – 0.59]
Random effects odds ratio/ effect size =0.37 [0.23 – 0.60]
Relapse 5 357
1st 12 months v. active treatments
Fixed effects odds ratio/ effect size= 0.89 [0.59 – 1.38]
Random effects odds ratio/ effect size = 1.67 [0.71 – 0.31]
Relapse 6 264
1-2 years v. all other treatments
Fixed effects odds ratio/ effect size= 0.74 [0.44 – 1.25]
Random effects odds ratio/ effect size = 0.57 [0.18 – 1.32]
Table 2: Summary of results extracted from included systematic reviews and meta-analyses.
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[27]
Relapse 5 148
1-2 years Single family treatments v. all other treatments
Fixed effects odds ratio/ effect size= 0.40 [0.19-0.84]
Random effects odds ratio/ effect size = 0.42 [0.11 – 1.64]
Relapse 4 228
Follow-up 4-15 months 
Single family treatments v. standard care
Fixed effects odds ratio/ effect size=  0.79 [0.46 – 1.37]
Random effects odds ratio/ effect size = 0.70 [0.27 – 1.76]
Readmission 4 242
1st 12 months v. all other treatments
Fixed effects odds ratio/ effect size= 0.57 [0.33 – 1.00]
Random effects odds ratio/ effect size = 0.38 [0.10 – 1.40]
Readmission 3 193
1st 12 months v. standard care
Fixed effects odds ratio/ effect size= 0.69 [0.37 – 1.27]
Random effects odds ratio/ effect size = 0.43 [0.08 – 2.28]
Readmission 3 143
1st 12 months Single family treatments
v. all other treatments
Fixed effects odds ratio/ effect size= 0.21 [0.09 - 0.49]
Random effects odds ratio/ effect size = 0.22 [0.09 – 0.51]
Readmission 6 638
1st 2 years v. All other treatments
Fixed effects odds ratio/ effect size = 0.60 [0.43 – 0.84]
Random effects odds ratio/ effect size = 0.47 [0.23 – 0.96]
Readmission 4 286
1st 2 years v. Standard care
Fixed effects odds ratio/ effect size= 0.51 [0.31 – 0.84]
Random effects odds ratio/ effect size = 0.39 [0.11 – 1.34]
Readmission 3 187
1st 2 years Single family interventions
v. Standard care
Fixed effects odds ratio/ effect size= 0.23 [0.11 – 0.46]
Random effects odds ratio/ effect size = 0.24 [0.12 – 0.47]
Readmission 4 253
Follow-up up to 2 years after v. Standard care
Fixed effects odds ratio/ effect size= 1.08 [0.64 – 1.81]
Random effects odds ratio/ effect size = 1.08 [0.64 – 1.83]
[41] Medication adherence 14 1435 Intervention group > comparison group: 3Intervention group = comparison group: 11
[28]
Relapse 3 213 Any family-based interventions vs. standard care0-6 months: RR = 0.71 [0.46 - 1.09]
Relapse 32 2981 Any family-based interventions vs. standard care7 - 12 months: RR = 0.55 [0.48 - 0.62]
Relapse 3 181 Any family-based interventions vs. standard care13 -18 months: RR = 0.64 [0.47 - 0.88]
Relapse 13 1019 Any family-based interventions vs. standard care19- 24 months: RR = 0.64 [0.55 - 0.75]
Relapse 4 497 Any family-based interventions vs. standard care25- 36 months: RR = 0.89 [0.72 - 1.10]
Relapse 1 63 Any family-based interventions vs. standard care5 years: RR = 0.88 [0.70 - 1.11]
Relapse 1 62 Any family-based interventions vs. standard care8 years: RR = 0.86 [0.71 - 1.05]
[12]
Relapse/
Rehospitalization 5 452
Post-assessment
effect size (Hedges' g) =0.53 [0.12 – 0.95]
Medication adherence 2 171 Post-assessment
effect size (Hedges' g) = −0.25 [−1.25 – 0.75]
Relapse/
Rehospitalization 4 387
Follow-up ≤6 months
effect size (Hedges' g) =0.35 [0.14 – 0.55]
Relapse/
Rehospitalization 7 362
Follow-up 7–12 months
effect size (Hedges' g) =0.48 [0.15 – 0.82]
Relapse/
Rehospitalization 3 144
Follow-up >12 months
effect size (Hedges' g) = 0.21 [−0.07 – 0.49]
[14]
Relapse
(for any reason) 11 1214 Medium term: RR=0.70 [0.61 - 0.81]
Relapse 
(for any reason) 11 1214 Long term: RR=0.73 [0.62 - 0.85]
Relapse 
(for any reason) 11 1214 Long term (5 years): RR=0.89 [ 0.73, 1.08 ]
Relapse 
(for any reason) 11 1214 Long term (7 years): RR=0.62 [0.42 0.92]
Relapse 
(with readmission ) 11 206 Medium term: RR= 0.77 [ 0.56, 1.07 ]
Relapse
(with readmission ) 11 206 Long term: RR = 0.71 [ 0.56, 0.89 ]
Compliance with medication/
non-compliance 10 1400 Short term: RR= 0.52 [0.40 - 0.67]
Compliance with medication/
non-compliance 6 781
Medium term: RR= 0.36 [0.27 – 0.49]
Compliance with medication-
non compliance 3 282 Long term: RR= 0.48[0.31-0.75]
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recent one [24], with just one study in common [25]. All other studies 
were specific to the review, 15 and 29 respectively (Table 3).
Regarding the reviews that we scored as having the best quality, 
seven studies were in common, corresponding to 26% of the Pekkala, 
et al. 2002 review and to33% of the Lincoln, et al. 2007 review [12,23].
The modest degree of overlap between reviews limits comparability 
of findings across reviews and undermines the judgment about the 
quality of evidence. 
Quality assessment
Quality assessment ratings for each included review is 
summarized in Table 4. 
For comparison, we also reported the quality rating concerning the 
four systematic reviews or meta-analyses on family psychoeducation 
covered in the Taylor, et al. 2009 meta-review on institutional care for 
people with long-term mental health problems [26].
In our scoring, one review only obtained a score below 50% of 
maximum score. Five out of nine included reviews scored above 
80% of the maximum score, indicating good quality of the review. 
The scoring of the reviews also covered in the Taylor, et al. 2009 
meta-review was similar to the present scoring, thus supporting the 
reliability of the judgment[26].
Evidence of relapse: Relapse as an outcome was covered in eight 
reviews out of nine, but collapsed the information with that on re-
hospitalization [12,14]. Risk of relapse was reported to be reduced 
in protocols that included family members, but not in interventions 
focussing on patients only. Family psychoeducation was reported 
to be effective whether conducted in single family or in multifamily 
group sessions [13]. Effectiveness seems not to be maintained at 
follow-up [27,28]. When relapse was considered together with 
re-hospitalization as an outcome, some evidence in favour of 
maintenance of effectiveness at follow-up was reported [12,14].
Evidence of hospital admission/re-hospitalization: Evidence 
of hospital admission/re-hospitalization was covered in four reviews 
out of nine. No evidence of a decrease of hospital admission/re-
hospitalization was reported in three reviews out of four. Xia, et al. 
2011 reported a reduction of the risk of relapse with readmission in 
the long term (RR = 0.71 [0.56, 0.89])[14].
Evidence of compliance/medication adherence: Compliance/
medication adherence was covered in three reviews out of nine. 
Two reviews found no effectiveness of family psychoeducation on 
compliance/medication adherence. Xia, et al. 2011 reported an 
improvement in the short, medium and long term, drawing evidence 
from ten, six and three independent studies, respectively [14]. The 
effects in the longterm were appreciable but with a wide(>0.25) 
confidence interval (RR= 0.48[0.31-0.75]).
Overall quality of evidence: Overall, quality of evidence on the 
effectiveness of family psychoeducation in schizophrenia is poor. 
There was limited overlap between the reviews of the included studies. 
[14]
Compliance with medication - partial 
compliance 3 472 Short term: RR= 0.64 [0.49, 0.85]
Compliance with medication - partial 
compliance 1 118 Medium term: RR =0.68 [0.39, 1.18]
It is therefore difficult to compare the findings of one review with 
another. The AMSTAR score was reasonably good for most reviews, 
but the risk of bias of the included studies was estimated in six reviews 
only.
In some reviews it was not clear whether RCTs only were included; 
in some reviews qualitatively different outcomes (e.g., relapse and 
re-hospitalization) were collapsed to produce an overall estimate 
of effectiveness. Most findings were doomed by imprecision (wide 
confidence intervals), or derived by less than 10 independent trials, 
which limits estimation of heterogeneity and bias in publication. 
Magnitude of effect, when present, was in the medium-to-low effect 
size, no dose-response could be established, and confounders were 
not properly addressed. 
Our evaluation agrees with that reported by Xia, et al. 2011 in 
their reviews, in which they judged the available evidence on the 
effectiveness of family psychoeducation to be low to very low [14].
Discussion
We reviewed the available evidence on the effectiveness of family 
psychoeducation in schizophrenia. Systematic reviews and meta-
analyses only were considered, since they are expected to convey 
the highest level of evidence in describing the strength of the results 
measured in a clinical trial or research study. Quality of evidence was 
assessed by both considering the adherence of each review to the 
current standard of review methodology, and taking into account 
studies’ findings andthe degree of confidence in their estimates.
We found that in the shortterm (at post treatment or shortly after) 
family psychoeducation was related to a consistent reduction of relapse 
into acute psychosis. The effect was mainly produced by protocols that 
included family members in the session, whether applied to a single 
family or to a multifamily group. This result did not translate into 
a consistent reduction of hospital admission/re-hospitalization over 
the medium/long-term and was not stable at follow-up. No evidence 
was found of an effect of family psychoeducation on compliance or 
medication adherence.
As already noted by Lincoln, et al. 2007, the heterogeneity of 
studies and the low numbers for most outcome categories produced 
effects with large confidence intervals, which hampers confidence 
on these estimates [12]. Overall, the low quality score that can be 
attributed to the grade of current evidence on the effectiveness of 
family psychoeducation suggests that further research is very likely to 
change both these estimates and the confidence that can be assigned 
to them.
Scarce or null effect on medication adherence discounts one of 
the explanations that were advanced to explain potential effectiveness 
of family psychoeducation, which was suggested to reduce relapse 
by increasing adherence to therapies. Alternative explanations on 
the effectiveness of psychoeducation purport a positive influence on 
family climate, by a lenient impact on expressed emotion [29], and 
improved problem-solving and coping skills in the patients and their 
Austin J Clin Neurol 4(2): id1107 (2017)  - Page - 06
Petretto DR Austin Publishing Group
Submit your Manuscript | www.austinpublishinggroup.com
A. Latest versus oldest meta-analysis
Xia, et al.  (2011) Dixon, et al. (1995)
List of included studies
1 Barrowclough, et al.  (1990) Falloon, et al. (1982)* Common =1
2 Bäuml, et al. (1996)* Falloon, et al. (1985)
3 Bäuml, et al.  (2007) Glick, et al. (1985)* Specific to Dixon, et al., 1995 =15
4 Buchkremer, et al.  (1997) Goldstein, et al. (1978)* Specific to Xia, et al., 2011 = 29
5 Chabannes, et al.  (2005)* Hogarty, et al. (1986)*
6 Chabannes, et al. (2008) Hogarty, et al. (1991)
7 Chan, et al. (2007)* Kottgen, et al. (1984)*
8 Chen, et al. (2005)* Leff, et al. (1982)*
9 Dai, et al.   (2007)* Leff, et al. (1985)
10 Dong, et al.  (2006)* Leff, et al. (1989)*
11 Feldmann, et al. (2000) Levene, et al. (1989)*
12 He, et al.  (2008) * McFarlane, et al.  (1994)*
13 Herz, et al. (1996) McFarlane, et al. (1995)*
14 Herz, et al. (2000)* Randolph, et al. (1994) *
15 Hornung, et al.  (1993) Schooler (1995)*
16 Hornung, et al.  (1995) * Tarrier, et al. (1988)*
17 Hornung, et al.  (1996) Vaughan, et al. (1992)*
18 Hornung, et al.  (1998) Zastowny, et al. (1992)*
19 Hornung, et al.  (1998b) 
20 Hornung, et al. (1999)
21 Hornung, et al.  (1999b) 
22 Jiang, et al. (2004)*
23 Kissling, et al.  (1999) 
24 Klingberg, et al.  (1999)
25 Li, et al.  (2004)*
26 Li, et al.  (2005)*
27 Li, et al. (2008)*
28 Liu, et al.  (2004)*
29 Merinder, et al.  (1999)
30 Merinder, et al.  (1998)
31 Merinder, et al.  (1998b)
32 Merinder, et al.  (2000)*
33 Pitschel-Walz, et al. (1993)
34 Pitschel-Walz, et al.  (1995)
35 Pitschel-Walz, et al.  (1997)
36 Pitschel-Walz, et al.  (2006)
37 Razali, et al. (1995)*
38 Razali, et al. (1997)
39 Sun, et al.  (2005)*
40 Tarrier, et al.  (1988)*
41 Tarrier, et al. (1989)
42 Tarrier, et al. (1990)
Table 3: Degree of overlap between representative meta-analyses.
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43 Wang, et al. (2008)*
44 Wang, et al. (2008b)*
45 Xie, et al. (2006)*
46 Zeng, et al. (2003)*
47 Zhang, et al.  (2003)*
48 Zhang, et al.  (2006)*
49 Zhang, et al. (2007)*
50 Zhang, et al.  (2007b)*
51 Zhang, et al. (2008)*
52 Zhao, et al. (2007)*
53 Zhou, et al.  (2005) *
B. Latest versus oldest meta-analysis among those with highest AMSTAR score
Pekkala, et al. (2002) Lincoln, et al.  (2007)
List of included studies
1 Barrowclough, et al. (1990) Atkinson, et al.(1996)* Common = 7
2 Bauml, et al. (1996)* Bäuml, et al. (1996)* Specific to Pekkala, et al., 2002= 6
3 Buchkremer, et al. (1997) Browne, et al. (1996)* Specific to Lincoln, et al., 2007= 18
4 Feldmann, et al. (2000) Chien, et al.(2004)*
5 Herz, et al. (1996) Chien, et al.(2005)
6 Herz, et al. (2000)* Fries, et al. (2003)*
7 Hornung, et al. (1993) Herz, et al. (2000)*
8 Hornung, et al. (1995)* Hornung, et al. (1995)*
9 Hornung, et al. (1996) Hornung, et al. (1999a)
10 Hornung, et al. (1998) Hornung, et al. (1999b)
11 Hornung, et al. (1998b) Leavy, et al. (2004)*
12 Hornung, et al. (1999) Leff, et al. (1982)*
13 Hornung, et al. (1999b) Li and Arthur (2005)*
14 Kissling, et al. (1999) Merinder, et al. (1999)*
15 Klingberg, et al. (1999) Posner, et al. (1992)*
16 Merinder, et al. (1998) Ran, et al. (2003)*
17 Merinder, et al. (1998b) Rund, et al. (1994)*
18 Merinder, et al. (1999) Shin and Lukens (2002)*
19 Merinder, et al. (2000)* Tarrier, et al. (1988)*
20 Pitschel-Walz, et al. (1993) Tomaras, et al. (2000) *
21 Pitschel-Walz, et al. (1995) Xiong, et al. (1994)*
22 Pitschel-Walz, et al. (1997)
23 Razali, et al. (1995)*
24 Razali, et al. (1997)
25 Tarrier, et al.  (1988)*
26 Tarrier, et al.  (1989)
27 Tarrier, et al.  (1990)
Notes to the table.
Asterisk (*) indicates studies whose results were entered in the meta-analysis.
Common studies are in bold.
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Dixon 
(1995)
Penn
(2001)
Pitschel-Walz 
(2001)
Pekkala 
(2002)
Pilling 
(2002)
Zygmunt 
(2002)
Pharoah  
(2006)
Lincoln 
(2007) Xia (2011)
1. Was an 'a priori' design provided? YES YES YES YES YES YES YES YES YES
2. Was there duplicate study selection and data 
extraction? YES NO YES YES YES YES YES YES YES
3. Was a comprehensive literature search performed? YES NO NO YES YES YES NO YES NO
4. Was the status of publication (i.e. grey literature) 
used as an inclusion criterion? YES NO YES
Cannot 
answer YES YES
Cannot 
answer YES
Cannot 
answer
5. Was a list of studies (included and excluded) 
provided? YES NO NO YES YES NO YES NO YES
6. Were the characteristics of the included studies 
provided? YES YES YES YES YES YES YES YES YES
7. Was the scientific quality of the included studies 
assessed and documented? YES
Cannot 
answer YES YES YES YES YES YES YES
8. Was the scientific quality of the included studies 
used appropriately in formulating conclusions? YES YES YES YES YES YES YES YES YES
9. Were the methods used to combine the findings of 
studies appropriate? NO
Cannot 
answer YES YES YES NO YES YES YES
10. Was the likelihood of publication bias assessed? NO NO YES YES YES NO YES YES YES
11. Was the conflict of interest stated? NO NO Cannot answer YES
Cannot 
answer YES YES YES YES
Tot YES 8/11(72%)
3/11
(27%)
8/11
(72%)
10/11 
(91%)
10/11
(91%)
8/11
(72%)
9/11
(81%)
10/11
(91%)
9/11
(81%)
Taylor (2009) Quality Assessment 12/14(85%)
14/14
(100%)
14/14
(100%)
14/14
(100%)
Table 4: AMSTAR evaluation.
relatives in the face of new psychopathological crises [10]. Whether 
one of these explanations or both are grounded is still undetermined.
Poor maintenance of the effects in the medium/long-term 
follow-up suggests that family psychoeducation does not translate 
into a stable change in family functioning. It can be advanced that 
family psychoeducation works as a form of supportive intervention, 
enabling families facing difficult situations to cope with them and 
receive emotional and practical support. Alternatively, it can be 
hypothesized that family psychoeducation produces adaptations 
that work in the current situation but do not generalize to new types 
of crisis. Either way, family psychoeducation would be effective 
when provided on a recurrent basis, without any expectation of any 
magical effects beyond its administration. Patients that discontinue 
drugs have a hugely enhanced risk of relapse into active psychosis 
[30]. Some psychosocial interventions should similarly require 
continuous administration to provide benefit. In planning such kind 
of interventions, costs of administration in terms of staff, time and 
location should be weighed against savings following reduction of 
relapse and, possibly, of re-hospitalization.
In the wake of the current financial cuts in the healthcare 
sector, it is encouraging that multifamily groups have a comparable 
effectiveness to single-family interventions. Preliminary evidence 
suggests that brief psychoeducational interventions-expected to be 
less expensive in terms of time and staff-can reduce relapse in the 
medium term when provided to people with severe mental illness, 
and favor medication compliance in the short term [31]. It is not clear 
how this evidence can generalize to family psychoeducation applied 
to people with schizophrenia, since quality of evidence was rated low 
[31].
It is worth mentioning that multimodal protocols of care 
addressing first-episode psychosis within the framework of the “early 
intervention” paradigm were able to produce measurable effects in 
the short term, which also translated into considerable cost curbing 
following lower hospitalization rates [32,33]. These positive effects 
tend to disappear after termination of the intervention [34,35].
Early intervention services usually include individual and family 
psychoeducation, cognitive behavioral therapy, and a wide range 
of both structured and unstructured psychosocial interventions 
(i.e., skills training group, school and professional training). These 
interventions are likely to contribute the most in the short term to the 
superiority of these protocols of care over treatment as usual (TAU). 
When these interventions cease, and pharmacotherapy remains the 
principal tool to treat patients with chronic schizophrenia, differences 
with TAU disappear [34].
An unexpected finding of this meta-review is the scarce overlap of 
primary studies among the reviews. It appears that different authors 
promote different criteria to include a study into a systematic review 
or a meta-analysis. When more stringent criteria are applied, evidence 
of the effectiveness of family psychoeducation for schizophrenia 
is attenuated in a range of outcomes [14]. The appraisal of these 
differences across reviews is important for stakeholders, particularly 
in long-term organizational decisions, such as those that derive from 
the inclusion of a recommendation in guidelines. Future systematic 
reviews are expected to be transparent in the definition of inclusion 
and exclusion criteria of the studies to be reviewed.
Conclusion
Narrative reviews are greatly more optimistic on the real 
effectiveness of family psychoeducation interventions [16], and 
on the basis of these optimistic reviews family psychoeducation is 
recommended as evidence-based practice in several guidelines for 
schizophrenia or severe mental illness [36-38]. The evidence drawn 
from meta-analyses is more conservative, and so far effects have 
been reported in the moderate-to-small range for risk of relapse 
[12,14], with small effects on psychosocial functioning [39]. It must 
be stressed that the expression “family psychoeducation” covers 
Austin J Clin Neurol 4(2): id1107 (2017)  - Page - 09
Petretto DR Austin Publishing Group
Submit your Manuscript | www.austinpublishinggroup.com
several approaches, which differ in their theoretical orientation, 
modality, and duration [39]. Conflating different models to the aim 
of quantitative analysis might obscure relevant aspects of the single 
intervention.
As a matter of fact, patients with psychosis often live in close 
contact with their relatives, who give them informal care and support. 
High levels of family burden and family stress (i.e., expressed emotion) 
result from the impact of the disorder on close relatives [29]. Despite 
this, the provision of family interventions is limited [40].
The results of this meta-review indicate the necessity of further 
studies on the effectiveness of family psychoeducation, to address 
inconsistencies in the literature and identify specific processes 
involved in the efficacy of the intervention (impact on family climate 
versus improved coping, and problem-solving versus promotion of 
adherence to pharmacotherapy) [41].
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